1. Home
  2. SRRK vs PCVX Comparison

SRRK vs PCVX Comparison

Compare SRRK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$47.49

Market Cap

6.8B

Sector

Health Care

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$54.42

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRRK
PCVX
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
7.0B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SRRK
PCVX
Price
$47.49
$54.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
4
Target Price
$56.17
$88.25
AVG Volume (30 Days)
1.0M
987.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$534.24
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.07
$29.10
52 Week High
$58.49
$65.00

Technical Indicators

Market Signals
Indicator
SRRK
PCVX
Relative Strength Index (RSI) 39.11 46.81
Support Level $45.83 $52.04
Resistance Level $48.23 $56.04
Average True Range (ATR) 2.20 2.38
MACD -0.65 -0.48
Stochastic Oscillator 5.15 25.98

Price Performance

Historical Comparison
SRRK
PCVX

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: